Keywords
Exercise, FNDC5, Irisin, UCP1
Exercise, FNDC5, Irisin, UCP1
We have implemented additional information regarding Irisin identification in content with the already existing argument in the text while we removed the detailed discussion of the most likely invalid ELISA. We have also included all the suggested information from the reviewers, regarding the differences that the existing studies displayed in the identification of the molecular weight of circulating Irisin. We removed repetition in the discussion section and redundancy in the results section. We have corrected minor errors in the Table 1 and the presented references in the text. As per the reviewers’ suggestions, we have included in the discussion two very important recent papers (Perakakis et al. 2017, Montes-Nieto et al. 2016).
See the authors' detailed response to the review by Fabian Sanchis-Gomar
See the authors' detailed response to the review by Elke Albrecht and Steffen Maak
Brown adipose-like phenotype in white adipose tissue (WAT) may play a role in reducing body weight, and consequently lessen obesity in mammals1. Recently, acute and chronic exercise has been found to induce a brown adipose-like phenotype in WAT2 through a number of sequential steps. Exercise is also known to increase the activation of the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) gene in human skeletal muscle3. PGC-1α is a co-transcriptional regulator facilitating multiple transcription factors to regulate a complex network of genes4 and it has been implicated in both the control of tissue mitochondrial content and the program that results in brown adipose tissue (BAT) formation5.
While skeletal muscle properly adapts to exercise in the absence of PGC-1α6, activation of PGC-1α was proposed to increase the fibronectin type III domain-containing protein 5 (FNDC5)2. FNDC5, is a membrane protein expressed in brain and skeletal muscle7. It was proposed that FNDC5 was cleaved during exercise, and released into the bloodstream as Irisin – a peptide fragment of FNDC5 measured by western blotting2. In vitro, exposure of white adipocytes to Irisin– through an unknown receptor – subsequently led to an increase of the peroxisome proliferator-activated receptor alpha, which in turn increased uncoupling protein one (UCP1) mRNA2. The increase in white adipocyte UCP1 mRNA observed with Irisin treatment, presented as fold-change over control, is hard to interpret since white adipocytes in culture do not usually express UCP1 mRNA8.
Since, UCP1 is the only contributor to non-shivering thermogenesis that occurs in BAT9 and it appears that the presence of UCP1 in a white adipocyte is accompanied by “brown-adipocyte like” properties8,10,11, it was proposed that increased circulating Irisin in humans after a chronic exercise program may promote increased weight loss and improved metabolic control through induction of UCP12. This hypothesis seemed superficially plausible, as Irisin over-expression stimulated oxygen consumption and has been described to have an inverse association with blood glucose, insulin, total cholesterol and a positive association with adiponectin concentrations12. However, other studies have failed to observe such positive associations13–15, while the effect of exercise on “browning” of the white adipose phenotype remains unclear16–18.
The exact role of exercise in regulating circulating Irisin concentration remains to be established. Indeed, data indicate that while older adults appear to have a 30% increase in FNDC5 mRNA in muscle compared to younger adults, FNDC5 mRNA was unresponsive to six weeks of endurance training19, despite robust increases in mitochondria20. In general, results on the effects of exercise on circulating Irisin17,21–24 have been rather ambiguous; diverse methodology may explain the highly discrepant results25,26. Given that Irisin continues to be measured using a variety of methods, an evaluation of the available evidence for its relationship with humans’ health is warranted, due to the potential that the browning of white adipocytes may have on human health. In addition, the proposed exercise mechanism that may cause a browning process of WAT in humans must be evaluated. Therefore, the aim of the current review was to systematically identify the effects of physical activity on the link between PGC-1α and FNDC5 in muscle, and circulating Irisin, as well as evidence for regulation of UCP1 in WAT (indicating a browning process) in humans.
Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines27–29, two databases (PubMed and EMBASE) were searched up until 19th August 2016. Two investigators (PCD and IML) independently conducted two identical searches in both databases using appropriate search algorithms (PubMed: Supplementary File 1; EMBASE: Supplementary File 2). The lists of the included articles were reviewed to identify publications that were relevant to the topic under review.
We included studies that met at least one of the following eligibility criteria: a) measurements of PGC-1a (mRNA and/or protein concentrations) in conjunction with measurements of FNDC5; b) measurements of FNDC5, and/or Irisin concentrations and/or UCP1 in WAT, along with the following criteria: c) measurements of physical activity levels and/or exercise interventions, and d) human participant study. No other eligibility criteria were set (e.g., language, date of publication). From the included studies, we retrieved outcomes regarding the effects of physical activity on PGC-1a in conjunction with FNDC5 in muscle, FNDC5 in muscle, Irisin in the bloodstream and UCP1 in WAT. We report the studies’ design, the participants’ characteristics, the Irisin identification and other outcome methods and study outcomes. We have also recorded the secondary associations in the included studies, i.e. associations between FNDC5 and/or circulating Irisin and several health-related phenotypes [e.g. energy expenditure, blood pressure, waist to hip ratio, body mass index (BMI)].
Two independent reviewers (PCD and GSM) evaluated the risk of bias of the studies included in the current review via the “Cochrane Collaboration’s tool for assessing risk of bias”30. Conflicts in the risk of bias assessment were resolved by IL and ADF. We also evaluated independently (PCD and GSM) the quality of reporting in the included randomised controlled trials (RCTs), controlled trials (CTs) and single group design studies (SGS) using the Consolidated Standards of Reporting Trials (CONSORT) checklist31, which is a 25-item checklist and we provided a score for each study included. For CTs and SGS, we used a modified CONSORT checklist comprised of 18 items, given that these studies are not RCTs and therefore, seven out of the 25 items of the CONSORT checklist are not applicable for CTs and SGS (i.e. randomization, blinding). We also evaluated independently (PCD and GSM) the quality of the reporting data of the included cross sectional studies (CSS) using the 22-item checklist of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and we also provided a score for each study included32. Disagreements on studies’ CONSORT and STROBE scores were arbitrated by IL and ADF. JT and PS then reviewed the molecular and genomic content of the review independent of the search process.
The reporting of the available information in this systematic review is shown in a PRISMA checklist in Supplementary Table 1.
The initial searching date was the 14th September 2015 while weekly alerts were received from both databases up until the 19th August 2016. Overall, the searching procedure revealed 51 studies that involved 2474 participants and met the inclusion criteria, and were therefore included in this systematic review. The reference lists of these studies did not result in the identification of additional relevant articles. The searching outcome is presented in a PRISMA flow diagram in Supplementary Figure 1.
The characteristics and the results of the included studies can be found in Table 1. From the 51 eligible studies, 12 (23.5%) were RCTs, of which four were cross-over RCTs, eight (15.7%) were CTs, 23 (45%) were SGS, and eight (15.7%) were CSS. One of the included RCTs33 reported the effect of resistance exercise training versus the effects of resistance exercise training combined with Ursolic supplementation, because for the latter group the effects of resistance exercise cannot be isolated, we will report only the results from the resistance exercise training group. Furthermore, one of the CTs34 will be included in the results of both CTs and CSS because this study consisted of a controlled trial nested within a CSS. Eight of the included studies examined overweight/obese adults and children17,35–41, while 11 studies included a clinical population, including patients with chronic obstructive pulmonary disease (COPD)23,34,42, heart failure43, metabolic syndrome44, haemodialysis45, osteoporotic46, anorexia nervosa36,47, pre-diabetes16 and diabetes type II48.
C-RCT: cross-over randomized controlled trail; F: females; M: males; AE: Acute exercise; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator 1α; FNDC5: Fibronectin type III domain-containing protein 5; PP: Phoenix Pharmaceuticals; NA: none available; CT: Controlled trial; CE: chronic exercise; UCP1: Uncoupling protein 1; WAT: White adipose tissue; CI: confidence interval; HOMA: homeostatic model assessment; CNS: Code not specified; SGS: Single group design studies; VO2max: Maximal oxygen uptake; CSS: Cross-sectional study; RCT: Randomized control trial; COPD: Chronic obstructive pulmonary disease; AB: Aviscera Bioscience; BMI: Body mass index; MetS: Metabolic Syndrome; LBM: Lean body mass; WHR: Waist to hip ratio; REE: Resting energy expenditure; VO2peak: peak oxygen uptake; WHR: waist to hip ratio; ATP: Adenosine triphosphate; PA: Physical activity; HDL: High density lipoprotein; METs: Metabolic equivalent.
The estimated risk of bias assessment results can be found in Table 2, and a summary is displayed in Supplementary Figure 2. Five RCTs44,49–52, and all the included CTs and CSS, as well as 22 of the 23 SGS, displayed a high risk of bias due to inadequate generation of a randomised sequence, while four RCTs23,33,42,53 showed low risk of bias, and three RCTs41,54,55, as well as one SGS56, showed unclear risk of bias because there was no description of the method used for allocation (even though the participants were said to be “randomly” assigned). Six RCTs23,42,49,50,52,53 displayed low risk of bias for “allocation concealment”, while two44,54 showed unclear risk of bias because of the lack of description of the randomization allocation. Also, four RCTs33,41,51,55, and all the included CTs and SGS, as well as CSS, showed high risk of bias due to the lack of concealment of allocations before assignment. In “blinding of participants and personnel”, all RCTs, CTs, SGS and CSS displayed high risk of bias because the exercise interventions could not be blinded to the participants.
In “blinding of outcome assessment”, three RCTs displayed low risk of bias23,53,54, while five RCTs42,44,49,50,52 and one CT16 showed unclear risk of bias because of the lack of information regarding the blinding of assessments. Also, four RCTs33,41,51,55, the remaining seven CTs, and all the included SGS and CSS showed high risk of bias due to the knowledge of the allocated interventions by the assessors. Seven RCTs23,33,41,42,51,53,54, one CT37, five SGS39,56–59 and one CSS60 displayed low risk of bias, while five RCTs44,49,50,52,55, the remaining seven CTs, the remaining 18 SGS and the remaining eight CSS showed unclear risk of bias for “incomplete outcome data” because of the lack of information on the participants who dropped out or exclusions in the analysis. All the included studies showed low risk of bias of “selective reporting” because they reported all the outcomes measured, and all the included studies displayed low risk of bias in “other bias”.
The results of our evaluation in the quality of the reporting data showed a mean score of 13.6 out of 25 (54.4%) for the included RCTs, 10.56 out of 18 (58.68%) for the included CTs and 10.52 out of 18 (58.44%) for the included SGS (Table 3). The CSS displayed a mean score of 13.37 out of 22 (60.8%) (Table 4). The score represents the number of items (with percentage of items) on the checklist that were reported satisfactorily in each study. Therefore, a high score represents a high adherence to reporting guidelines, while a low score represents low adherence to reporting guidelines.
Score represents the number of items (with percentage of items) on the checklist that were reported satisfactorily in each study. Therefore, a high score represents a high adherence to reporting guidelines, while a low score represents low adherence to reporting guidelines.
Score represents the number of items (with percentage of items) on the checklist that were reported satisfactorily in each study. Therefore, a high score represents a high adherence to reporting guidelines, while a low score represents low adherence to reporting guidelines.
The link between PGG-1a and FNDC5 in muscle in response to physical activity/exercise
Acute effects of exercise
Five studies16,17,50,61,62 investigating the link between PGC-1α with FNDC5 in muscle in response to acute exercise showed an increase of the PGC-1α mRNA in muscle; however, only two studies16,62 also found an increase in muscle FNDC5 mRNA, while one study43 detected a positive association of PGC-1α with FNDC5 in muscle. More specifically, a study found that an aerobic (2.1±0.8-fold over baseline, p=0.05) and a resistance (3.5±0.9-fold over baseline, p=0.01) training session increased PGC-1α splice variant1 but it did not change FNDC5 mRNA in the muscle of healthy adults50. Similarly, a resistance training session increased PGC-1α splice variant1 four hours post exercise (200%, over baseline and over control, p<0.05), but it did not change FNDC5 mRNA in the muscle of healthy adults61. A 45-minute endurance exercise session increased Exon 11 of PGC-1α mRNA in muscle (7.4-fold over baseline, p<0.05), but it did not change FNDC5 mRNA in muscle in both healthy and pre-diabetic adults, while a positive association between PGC-1α and FNDC5 mRNA was found at baseline (r=0.82, p<0.01) when data of the two groups were combined16. Furthermore, PGC-1α mRNA in muscle increased (>6-fold over baseline, p<0.05) in response to acute exercise; however, FNDC5 mRNA in muscle was not altered in sedentary overweight and obese adults17. Also, a resistance exercise session increased Exon 11 of PGC-1α mRNA in muscle of both young (4-fold over baseline, p<0.05) and older (2-fold over baseline, p<0.05) healthy adults, while it increased FNDC5 mRNA in muscle only in young (1.4-fold over baseline, 95% Confidence Interval=0.3–2.2, p<0.05) healthy adults62. Finally, PGC-1α mRNA in muscle was positively associated with FNDC5 mRNA in muscle (r=0.56, p<0.05) in a sub-set of 24 patients with heart failure43; stratification was ad hoc.
Chronic effects of exercise
Of the eleven eligible studies2,16–19,40,62–67 that examined the link between PGC-1α with FNDC5 in muscle in response to chronic exercise, only two16,66 showed that chronic exercise increased PGC-1α and FNDC5 mRNA in muscle, while four studies18,19,62,63 showed no effect of chronic exercise on PGC-1α and FNDC5 mRNA in muscle. In the five studies that only measured FNDC5 in muscle, one study2 found increased and four17,40,64,65 showed no effect of chronic exercise on FNDC5 mRNA in muscle.
A 12-week of endurance and resistance combined exercise training increased Exon 11 of PGC-1α mRNA in muscle (1.2-fold in healthy and 1.6-fold in pre-diabetic adults over baseline, p<0.05) and FNDC5 mRNA in muscle (1.4-fold in healthy and 2-fold in pre-diabetic adults over baseline, p<0.05)16. Furthermore, an 8-week sprints exercise program increased PGC-1a and FNDC5 mRNA in muscle (p<0.05) in healthy adults66. Finally, Bostrom et al. (2012) showed that in eight older participants selected from a larger group of 27 participants, chronic exercise increased FNDC5 mRNA in muscle (p<0.05)2.
A 21-week endurance and resistance combined exercise program in healthy adults did not alter PGC-1α and FNDC5 mRNA in muscle62. One of the included studies19 found no effect of chronic exercise on PGC1a or FNDC5 mRNA in younger adults (despite detecting significant changes in ~1,000 other mRNAs and finding mitochondrial enzyme activity was increased in ~25%)68. Similarly, an 8-week resistance exercise program did not alter PGC-1α or FNDC5 mRNA in muscle of young healthy adults63. In addition, 12 weeks of resistance training did not alter PGC-1α splice variant1 mRNA, and it did not change the FNDC5 mRNA in muscle in untrained young females18. Also, a 12-week aerobic and resistance exercise combined program17 and an 8-week aerobic exercise program40 did not alter FNDC5 mRNA in muscle of sedentary obese adults, while chronic exercise had no effect on FNDC5 mRNA in muscle of healthy adults64. Finally, a 3-week sprint interval training program did not alter FNDC5 mRNA in muscle of healthy adults65.
The effects of physical activity/exercise on Irisin
Acute effects of exercise
Studies using enzyme-linked immunosorbent assays (ELISA)
Eighteen of the included studies12,17,21,22,34,35,38,44,49,50,52,56,58,62,66,69–71 examined the effects of acute exercise on circulating Irisin, and a further seven studies34,36,46–48,60,72 investigated the association of circulating Irisin with physical activity levels using commercial ELISA kits. Thirteen studies12,21,22,38,44,49,50,52,58,66,69–71 showed that acute exercise increased circulating Irisin in healthy individuals, while five studies17,34,35,56,62 showed no effect of acute exercise on circulating Irisin. Also, three studies34,48,60 showed a positive association of circulating Irisin with physical activity levels in healthy and COPD patients, while four studies36,46,47,72 showed no association or a negative association of circulating Irisin with physical activity levels in both healthy and clinical populations.
A resistance training session did not change FNDC5 mRNA in the muscle of healthy adults and circulating Irisin increased (p<0.001) over the following 24-hour50, indicating no short-term association between FNDC5 and Irisin. Furthermore, an aerobic exercise session increased circulating Irisin (p=0.04) and Irisin concentrations were measured at ~355–459 ng/ml50, greater than recent mass spectrometry measurements73. Similarly, a running exercise session in healthy individuals49 and an aerobic exercise session, as well as a resistance exercise session, in healthy individuals and in metabolic syndrome patients44 increased circulating Irisin (p<0.05). In the latter studies, Irisin concentrations measured at ~99–175 ng/ml49 and ~80–94.6 ng/ml44, respectively, which is greater than recent mass spectrometry measurements73. Also, an acute resistance exercise session increased circulating Irisin (p<0.05) as oppose to aerobic and combined (aerobic and resistance) sessions that did not alter circulating Irisin in healthy males (Irisin concentrations ~18–151 ng/ml)52. Furthermore, a 90-minute aerobic exercise session increased circulating Irisin during (54th minute) the exercise session (20.4% compared to baseline, F(3,36)=5.28, p=0.004), but circulating Irisin decreased after the exercise session (p=0.021) in healthy male adults69. In the latter study, the aerobic exercise session also increased circulating Irisin during (54th minute) the exercise session (F(3,24)=5.03, p=0.01) in healthy female adults69. Eight out of the 23 included SGS showed that acute exercise increased circulating Irisin in healthy populations12,21,22,38,58,66,70,71, while a resistance exercise session increased FNDC5 mRNA in muscle only in young healthy adults and it did not alter circulating Irisin of both young and older healthy adults62. In addition, 45 minutes of running did not alter circulating Irisin in obese healthy adults35. Similarly, an acute cycling session did not alter circulating Irisin in COPD patients34, while an acute exercise session did not alter FNDC5 mRNA in muscle or circulating Irisin in sedentary overweight and obese adults17. Finally, an acute exercise session of both low and high intensity resistance training did not alter circulating Irisin (p>0.05) in sedentary young healthy females (Irisin concentrations ~69–87 ng/ml)56.
Physical activity levels were positively associated with circulating Irisin in healthy adults (r=0.20, p=0.03), but not in patients with diabetes type II48, and they were not associated with circulating Irisin in osteoporotic women46 and in anorexic women47. Furthermore, circulating Irisin concentrations were higher in physically active (Irisin concentrations 128.55±78.71 ng/ml) than in sedentary individuals (Irisin concentrations 105.66±60.2 ng/ml) (p=0.006)72. However, physical activity levels were negatively associated with circulating Irisin (r=−0.22, p=0.001) in groups of anorexic, obese and healthy women36, while they were positively associated with circulating Irisin in both COPD patients (r=0.83, p<0.01) and healthy individuals (r=0.79, p<0.001)34. Finally, circulating Irisin was positively correlated with physical activity levels in individuals who demonstrated high weekly physical activity energy expenditure (2050–3840 kcal/week) (Irisin concentrations ~32–261 ng/ml, p=0.04).
Studies using mass spectrometry and western blotting
Only one included study used both western blotting and mass spectrometry to detect circulating Irisin in response to acute exercise. This study showed that submaximal acute aerobic exercise increased circulating Irisin (3.1-fold over baseline, p<0.05), whereas maximal acute aerobic exercise did not alter circulating Irisin, even though tended to be significant (p=0.07), in two healthy volunteered adults24.
Chronic effects of exercise
Studies using ELISA
Twenty three included studies12,16,18,22,23,33,34,37,39,41,42,45,51,53–57,59,62,65,70,74 in the current review examined the effects of chronic exercise on circulating Irisin using commercial ELISA kits, while the populations examined showed large heterogeneity. Nine studies23,34,39,41,51,54,59,65,74 showed that chronic exercise increased circulating Irisin, while 12 studies12,16,18,22,33,37,42,45,53,57,62,70 showed no effects of chronic exercise on circulating Irisin, and two studies showed that chronic exercise decreased circulating Irisin55,56, in both healthy and clinical populations.
A 6-month resistance training program increased circulating Irisin in healthy controls (p<0.01), but not in the exercisers54, while an 8-day vibration exercise increased circulating Irisin in COPD patients (p=0.01)23. Notably, the Irisin concentrations in the latter study23 were ~785–1196 ng/ml, a lot greater than recent mass spectrometry based detection of Irisin concentrations73. Furthermore, a 12-week resistance exercise increased circulating Irisin in elderly healthy females (Irisin concentrations ~61–83 ng/ml, p<0.05,)51. In addition, a 12-week of endurance and resistance combined exercise training in both healthy and pre-diabetic adults increased FNDC5 mRNA in muscle, while it decreased circulating Irisin (p<0.05) when the data of both healthy and pre-diabetic groups were combined16. In the latter study, Irisin concentrations were detected at 160 ng/ml at baseline and 143 ng/ml after the exercise program, a lot greater than recent mass spectrometry based detection of Irisin concentrations73. In addition, an 8-week endurance training program increased circulating Irisin only in middle-aged and not in young healthy adults (Irisin concentrations ~140–168 ng/ml, p<0.05)74, while an 8-week chronic exercise program in COPD patients increased circulating Irisin (p<0.05)34. Finally, a 12-month physical activity intervention increased circulating Irisin by ~12% (p=0.001) in obese children39. Notably, in the latter study, Irisin concentrations were 111 ng/ml, a lot greater than recent mass spectrometry based detection of Irisin concentrations73.
A 3-week sprint interval training program did not alter FNDC5 mRNA in muscle and showed a gender difference in circulating Irisin, which was decreased in healthy males and increased in healthy females (p<0.05)65. An 8-week resistance exercise training program increased circulating Irisin compared to control group (p<0.05), while the Irisin concentrations were ~700–850 ng/ml41. Similarly, 3-month cross-fit training increased circulating Irisin (Irisin concentrations ~300–850 ng/ml, p<0.05) only in females59. On the other hand, a 4-week sprint exercise training decreased circulating Irisin (Irisin concentrations ~200-340 ng/ml, p<0.05) in healthy males55. Three months of both non-individualized training and individualized training did not alter circulating Irisin (Irisin concentrations ~123–131 ng/ml, p>0.05) in COPD patients42. Finally, an 8-week low intensity resistance training program did not alter circulating Irisin, while an 8-week high intensity resistance training program reduced circulating Irisin (Irisin concentrations ~51–87 ng/ml, p=0.03)56.
An 8-week resistance training program in healthy adults did not alter circulating Irisin33 and a 26-week aerobic exercise program revealed no changes in circulating Irisin of healthy adults53. A 21-week endurance and resistance combined exercise program in healthy adults did not alter FNDC5 mRNA in muscle and circulating Irisin62. Similarly, a 16-week resistance exercise program in elderly women did not increase circulating Irisin37 and 12 weeks of resistance training did not alter FNDC5 mRNA in muscle or circulating Irisin18. However, circulating Irisin was positively correlated with FNDC5 mRNA in muscle (r=0.65, 95% Confidence Interval=0.12–0.89, p<0.05) in the latter study18. Finally, five SGS showed that chronic exercise did not alter circulating Irisin in healthy individuals12,22,57,70 and haemodialysis patients45.
Studies using mass spectrometry and western blotting
Only two included studies used alternative methods than commercial ELISA kits to detect human circulating Irisin in response to chronic exercise. Initially, Bostrom et al. (2012) showed via western blotting that in eight older participants selected from a larger group of 27 participants67 chronic exercise increased FNDC5 mRNA in muscle (p<0.05) and circulating Irisin (2-fold over baseline, p<0.05)2. Finally, one study contrasted plasma Irisin concentrations in six younger individuals following 12 weeks high intensity aerobic exercise with those found in a separate group of four individuals (no pre-training samples were presented)73. This study used mass spectrometry and detected circulating Irisin at 3.6 ng/ml in controls and 4.3 ng/ml in exercisers, which was significantly different between the two groups (p=0.04). No details regarding training or control of hydration in the training group were reported73.
We located only one study that examined the effects of exercise on UCP1 mRNA in subcutaneous WAT in humans. This study found that a 12-week intervention of endurance and resistance combined exercise in both healthy and pre-diabetic adults had no significant effect on UCP1 mRNA in subcutaneous WAT, even though UCP1 mRNA was increased (1.82-fold over baseline, p<0.05) when data from both groups were combined16. Also, UCP1 mRNA did not associate with FNDC5 mRNA in muscle (r=0.28, p=0.18) and circulating Irisin (r=-0.11, p=0.60)16.
The secondary results of the included studies can be found in Table 1. In 118 muscle profiles, FNDC5 mRNA was modestly and positively correlated with BMI (r2=0.1, p=0.004), while FDNC5 mRNA was not related to fasting glucose or glycaemic control19. Furthermore, circulating Irisin was not associated with inflammatory indices39, blood glucose62,65, homeostatic model assessment (HOMA)62,65,71, insulin62,65,71, leptin71, lean body mass46,57, fat mass18,46,57, waist to hip ratio71, energy expenditure21,54, BMI71, and pulmonary function34.
Additional secondary results show that circulating Irisin was positively associated with BMI59,70,72,75, triglycerides70,72, fat mass36,59, HOMA72, insulin72, blood glucose71 and leptin75, and negatively with high density lipoprotein cholesterol70, all of which indicate unfavourable effects of Irisin on human health. Nevertheless, some secondary evidence suggests that circulating Irisin was positively associated with fat free mass36,70, muscle mass41 and energy expenditure36, and Irisin that was incubated within white adipocytes in vitro increased glucose and fatty acids uptake66. Furthermore, circulating Irisin after a maximal workload was significantly greater in individuals with higher VO2max than individuals with lower VO2max21. However, circulating Irisin was not associated with VO2peak before and post exercise in healthy females57 and sedentary overweight and obese individuals, while it was inversely correlated with VO2peak (p<0.05) in healthy males60.
The aim of the current review was to systematically identify the effects of physical activity on the link between PGC-1a and FNDC5 in muscle and circulating Irisin, as well as evidence for regulation of UCP1 in WAT (indicating a browning process) in humans.
We were unable to find strong evidence that links PGC-1α and FNDC5 mRNA in muscle in response to exercise training or increased physical activity levels. Notably, we located only one study that examined the effects of exercise on UCP1 in WAT, and this found no effect16. Despite PGC-1α being firmly placed as a central regulator of adaptation to exercise in mice and humans, numerous aspects of the literature are contradictory or incomplete. For example, previous evidence indicates that PGC-1α mRNA accumulates with endurance training, while studies of PGC-1α protein reflect various antibodies that measure distinct molecular entities ranging from 70 to >110 kDa76–78. Furthermore, mice lacking PGC-1α adapt normally to endurance exercise training, and in humans the PGC-1α regulated gene network does not correlate with aerobic adaptation68. Thus any argument that places Irisin as part of the core PGC-1α regulated exercise adaptation program needs to reflect, on both technical and theoretical grounds, that there is great uncertainty of the nature and importance of PGC-1α in exercise and health79.
When PGC-1α protein content is measured (albeit with uncertainty over protein identities) exercise training increases PGC-1α protein in skeletal muscle or causes nuclear translocation of protein80–83. However, the studies included in the current review only relied on measuring PGC-1α mRNA to determine the effects of exercise on PGC-1α, and the time-course of mRNA and protein responses to exercise are distinct. Thus, the link between PGC-1α and FNDC5 in skeletal muscle may reflect measurement of mRNA dynamics and this may explain inconsistent findings for PGC-1α. Also, the proposed mechanism by Bostrom et al. (2012) indicates that induction of PGC-1α mRNA and then protein would activate the transcription of FNDC5, and hence, if this theory was correct, it would be expected that a strong correlation between PGC-1α mRNA and FNDC5 mRNA would exist. However, previous evidence showed that FNDC5 mRNA in muscle is not regularly increased by exercise or differently regulated between those with and without insulin resistance19, and was only modestly increased in a subset of older people following chronic exercise training19. If we focus on more reliable mRNA measures of PGC-1α and FDNC5, then the variable findings may be explained by the different characteristics of the populations examined and the different exercise protocols used.
An interesting aspect brought forward in the included studies showed that the start codon of the FNDC5 gene displays a variation in humans due to the non-ATG start codon64. In humans, ATG is usually the first codon to lead to efficient protein production, and therefore, the latter may suggest that Irisin, if produced, would be done so in an inefficient manner64. However, this notion has been questioned by a subsequent study, which supports that human Irisin is mainly translated from its non-ATG start codon, while the molecular weight of the protein is similar to that of important proteins in human body, such as insulin, leptin and resistin73, indicating a biological role of Irisin.
The various commercially available antibodies used in the ELISA kits of the studies included in the current systematic review, yield a protein concentration that appears to be ~5–278 times greater than a more recent mass spectrometry data (data that may require independent validation), and still far above what others have found84. Furthermore, Kurdiova et al. (2014) reported poor agreement between ELISA kit RK-067-16 and EK-067-29 (Phoenix Pharmaceuticals)17. Similarly, no correlation was found between EK-067-52 and ELISA of Adipogen that were used in the same samples26. Finally, Montes-Nieto et al. (2016) analysed human Irisin using two different lots (604824 and 605835) of the ELISA kit EK-067-29 (Phoenix Pharmaceuticals) and also found a poor agreement (r=0.226) between them85. These technical considerations may explain part or all of the equivocal results of the included studies in this current review regarding circulating Irisin.
According to the results of the current systematic review, two studies have measured circulating Irisin via mass spectrometry in response to exercise in humans. In the study by Jedrychowski et al. (2015), blood samples for Irisin identification were collected only after the exercise program from a small number of participants who were sedentary (n=4) or aerobic exercisers (n=6)73. In the study by Lee et al. (2014), Irisin was measured only pre and post-acute exercise without a control situation, and the sample size was only two participants24. Also, in the latter study a ~3-fold increase of Irisin was reported only after submaximal and not maximal exercise. These studies display methodological limitations and a small number of participants, which indicates that future longitudinal studies of changes in Irisin will clarify if the mass spectrometry measures reflect exercise-induced changes. Furthermore, Bostrom et al. (2012) and Lee et al. (2014) used an antibody that is discontinued for Irisin identification, given that it recognises a peptide of FNDC5 that is not part of the sequence of the secreted Irisin as this identified by mass spectrometry73, while Jedrychowski et al. (2015) used an antibody by Adipogen. This may explain the discrepancy in the molecular weight of Irisin between those analysed by Bostrom et al. (2012) and Lee et al. (2014) (~22 kDa) and those analysed by Jedrychowski et al. (2015) (~12 kDa). While the studies that utilised mass spectrometry do not agree24,73, reflecting issues of sensitivity and methodology, the latest identification and analysis of Irisin24,73 indicates that Irisin may circulate in blood and probably has a similar or identical structure to the mouse structure; however, whether it has genuine biological activity remains to be elucidated.
Based on the studies selected for the purposes of the current review, we cannot reach precise conclusions regarding the effects of acute and chronic exercise on PGC-1α in conjunction with FNDC5 mRNA in muscle; this is mainly due to the inconsistency of the findings and the different population characteristics examined. Most of the RCTs33,44,49–52 display high risk of bias, due to inadequate generation of a randomised sequence and a lack of concealment of allocations before assignment, while all the RCTs exhibit high risk of bias since the exercise interventions could not be blinded to the participants. In addition, four RCTs44,49,50,52 display unclear risk of bias because of the lack of information regarding the blinding procedures. Therefore, the risk of bias assessment of the included RCTs indicates that they may provide imprecise results (Table 2). In addition, the CTs and SGS display a high risk of bias due to the absence of generation of a randomised sequence, inadequate concealment of allocations before assignment and knowledge of the allocated interventions by the outcome assessors. They also display unclear risk of bias due to knowledge of the allocated interventions by the investigators during the study (Table 2). Finally, the included CSS display high risk of bias due to inadequate generation of a randomised sequence, lack of concealment of allocations before assignment and knowledge of the allocated interventions by the assessors, while they display unclear risk of bias for “incomplete outcome data” because of the lack of information of the participants who were excluded from the analysis. This evidence indicates that the CTs, SGS and CSS may also provide imprecise results. Furthermore, quality of reporting, as expressed through the adherence guidelines (i.e. CONSORT and STROBE), showed low scores of the required results that should have been reported (54.4% for RCTs, 58.68% for CTs, 58.44% for SGS and 60.8% for CSS) by the included studies in the current review. This shows inadequate reporting of the results of the included studies that may not aid the critical appraisal and interpretation of their outcomes.
To the best of our knowledge, this is the first systematic review that examines the effects of physical activity on the link between PGC-1α and FNDC5 in muscle, circulating Irisin and on UCP1 of WAT in humans. We compared our results with a recent meta-analysis that aimed to identify the effects of exercise on circulating Irisin86. This meta-analysis concluded that chronic exercise may decrease circulating Irisin in the RCTs while the non-RCTs cannot form any conclusion. However, the latter meta-analysis did not take into consideration the issues raised regarding the validity of the methods used for Irisin identification26. In contrast, while we considered the methods used for Irisin identification in the studies included in the current review, our review had a different aim, to systematically identify the effects of physical activity on the link between PGC-1α and FNDC5 in muscle, circulating Irisin and find evidence for regulation of UCP1 in WAT in humans. Regarding circulating Irisin, we also report that we cannot form any firm conclusion of the effects of exercise on circulating Irisin. Our review highlights previous evidence showing that circulating Irisin may only be detected in humans via mass spectrometry25,26,73, while we suggest that the previous available data coming from methods that have not been previously validated for circulating Irisin identification should not be used. This is because recent evidence questioned the antibodies used in the commercial ELISA kits given the polyclonal nature of these antibodies that may attract cross-reacting proteins26. However, publications that use commercial ELISA that have not been previously validated to detect human Irisin continue at an alarming rate. Therefore, our review indicates to consider using only valid methods for human circulating Irisin identification in the future. Furthermore, our results are in accordance with a previous review that showed equivocal results among studies examining circulating Irisin due to the methodological variations for Irisin detection87. In this critical review, the authors examined the commercial antibodies and ELISA used to measure circulating Irisin and concluded that the currently available antibodies should be tested for cross-reacting antigens detection87. Additionally, another recent review showed that the previous measurements for circulating Irisin identification differs greatly, given that they displayed a molecular weight of the protein between 0.01 ng/ml and 2000 ng/ml88. The latter critical review concluded that it is necessary to establish accurate methods for irisin measurements. Our systematic review analysis, agrees with the latter conclusion given that the Irisin measurements in the included studies via commercial ELISA kits, displayed a molecular weight of the protein ranging between 22 ng/ml to 1196 ng/ml.
Initially, Irisin was proposed to have a therapeutic effect given the potential to cause a browning formation of WAT that may have anti-obesity and antidiabetic effects2. This was mainly suggested when Irisin administered in obese mice improved glucose homeostasis and caused weight loss2. Also, the browning formation that Irisin may cause could lead to reduced weight gain, up-regulated insulin sensitivity, reduced risk of diabetes type II and other metabolic disorders as animal studies indicate89–93, as well as increase daily resting energy expenditure in humans94,95. The available evidence from the included studies in the current review revealed that the available commercial ELISA kits for Irisin identification either were found to be invalid26,87 or they should be tested for validity87. Thus, we cannot confirm a favourable effect of Irisin on human metabolism. Finally, none of the included studies in the current review examined associations of circulating Irisin with indices indicate a therapeutic role of the protein using western blotting and/or mass spectrometry methods.
The current review has a number of strengths. For instance, we used the PubMed and the EMBASE databases using appropriate algorithms with standardized indexing terms. Standardized indexing terms can retrieve records that may use different words to describe the same concept and information beyond that may be contained in the words of the title and abstract96. Furthermore, the current review used a systematic manner to identify articles according to previous methodology27–29, and we used well-established tools30–32 to evaluate the included studies. To reduce bias, two investigators worked independently on the screening of the included studies for eligibility, risk of bias assessment, and in the provision of CONSORT and STROBE scores. Also, we have not excluded studies based on language. However, a limitation of the current review includes the use of only published literature; we did not include grey literature searching. In this light, there is a potential of publication bias in the current review. Nevertheless, the inclusion of grey literature may itself introduce bias and one reason to include grey literature would be the absence of peer-review sources96.
We found little evidence to determine the link between PGC-1a mRNA and FNDC5 mRNA in human muscle, and there was limited evidence on the effects of physical activity on UCP1 in subcutaneous WAT. We also found a heterogeneity in the populations examined, high risk of bias by the selected studies and a relatively small number of RCTs (n=12) with inconsistent findings regarding the link between physical activity, PGC-1a, FNDC5, and UCP1.
Mass spectrometry detection of Irisin of exercise effects were compromised by the methodological limitations of the existed studies (i.e. post exercise comparisons, lack of control, small samples). The current systematic review highlights previous evidence that indicates via mass spectrometry that Irisin is present in human blood at concentrations that are ~5–278 folds lower than those detected by commercial ELISA kits. Therefore, we are unable to conclude on the circulating Irisin response to physical activity due to methodological limitations. In this regard, our systematic review used well-established methodology (i.e. PRISMA and Cochrane Library guidelines). However, we have also considered the validity and accuracy of the measurements of Irisin protein concentrations in the included studies. This additional analysis completely redirected our conclusion compared to the conclusion that a well-established systematic review methodology would provide. Therefore, we suggest that future systematic reviews should also take into consideration the validity and accuracy of the measurements of the included studies, to avoid misleading conclusions. We also suggest that future studies should only consider currently valid methods for human circulating Irisin (i.e. mass spectrometry), until new methods are introduced. The latter also implies that future studies should re-examine the biological role for human Irisin and the effects of physical activity/exercise on the link between PGC-1a and FNDC5 in muscle, circulating Irisin and UCP1 in WAT.
PCD and IML formed the paper, developed the algorithms and conducted the searching procedure. PCD and GSM performed the risk of bias and the quality of the reporting of the results assessments. Disagreements in the assessment of both risk of bias and the quality of the reporting of the results was arbitrated by IML and ADF. JT and PS contributed in the data extraction from the selected studies, reviewed and modified the molecular and genomic content of the paper. YK contributed in the data extraction from the selected studies, reviewed and modified the content of the manuscript. All authors approved the submitted version.
PCD and ADF were supported by the European Union 7th Framework Programme [FP7-PEOPLE-2012-IRSES (FUEGO grant no. 612547), and FP7-PEOPLE-2013-IRSES (U-GENE grant no. 319010)]. PS was supported by the Swedish Federal Government under the LUA/ALF agreement (grant no. ALFGBG-431481).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Supplementary File 1: PubMed search.
Click here to access the data.
Supplementary File 2: EMBASE search.
Click here to access the data.
Supplementary Table 1: PRISMA checklist.
Click here to access the data.
Supplementary Figure 1: PRISMA flow diagram of study selection and identification.
Click here to access the data.
Supplementary Figure 2: Summary of risk of bias assessment using the Cochrane Collaboration’s tool.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
References
1. Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, et al.: Physiology and role of irisin in glucose homeostasis.Nat Rev Endocrinol. 2017. PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
References
1. Montes-Nieto R, Martínez-García MÁ, Luque-Ramírez M, Escobar-Morreale HF: Differences in analytical and biological results between older and newer lots of a widely used irisin immunoassay question the validity of previous studies.Clin Chem Lab Med. 2016; 54 (7): e199-201 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 26 May 17 |
read | |
Version 1 17 Mar 17 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)